{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(3)"],"submitter":["Xu J"],"funding":["Simcere Pharmaceutical Group supported the present study"],"pubmed_abstract":["Background
Edaravone Dexborneol is a novel neuroprotective agent that comprised edaravone and (+)-borneol, a food additive with an anti-inflammatory effect in animal ischaemic stroke models. This study aims to assess the safety and efficacy of Edaravone Dexborneol compared with edaravone in treating patients with acute ischaemic stroke (AIS).Methods
In this multicentre, randomised, double-blind, multiple-dose, active-controlled, phase II clinical trial, patients with AIS within 48 hours after stroke onset were randomly assigned (1:1:1:1) to low-dose (12.5 mg), medium-dose (37.5 mg) or high-dose (62.5 mg) Edaravone Dexborneol groups, and an active control group with edaravone (30 mg) by 30 min intravenous infusion every 12 hours, for 14 consecutive days. The primary efficacy"],"journal":["Stroke and vascular neurology"],"pagination":["109-114"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6812637"],"repository":["biostudies-literature"],"pubmed_title":["Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial."],"pmcid":["PMC6812637"],"pubmed_authors":["Wang A","Gao Z","Gao X","Chen H","Wang Y","Xu J","Zhou J","Zhao X"],"additional_accession":[]},"is_claimable":false,"name":"Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial.","description":"Background
Edaravone Dexborneol is a novel neuroprotective agent that comprised edaravone and (+)-borneol, a food additive with an anti-inflammatory effect in animal ischaemic stroke models. This study aims to assess the safety and efficacy of Edaravone Dexborneol compared with edaravone in treating patients with acute ischaemic stroke (AIS).Methods
In this multicentre, randomised, double-blind, multiple-dose, active-controlled, phase II clinical trial, patients with AIS within 48 hours after stroke onset were randomly assigned (1:1:1:1) to low-dose (12.5 mg), medium-dose (37.5 mg) or high-dose (62.5 mg) Edaravone Dexborneol groups, and an active control group with edaravone (30 mg) by 30 min intravenous infusion every 12 hours, for 14 consecutive days. The primary efficacy","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Sep","modification":"2026-06-15T06:07:36.413Z","creation":"2026-06-15T03:08:11.304Z"},"accession":"S-EPMC6812637","cross_references":{"pubmed":["31709115"],"doi":["10.1136/svn-2018-000221"]}}